Therapeutic Benefit of Baseline PSA

September 11, 2013

Therapeutic Benefit of Baseline PSA: Lower Baseline PSA is Associated with a Greater Overall Survival Benefit from Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial

Dr. Leonard Gomella discusses an important topic that has been further defined based on the registration trial for sipuleucel-T, namely the therapeutic benefit that is seen in patients based on baseline PSA.

Click HERE to read an exclusive report by a UroToday medical writer

Leonard G. Gomella, MD, FACS - BIO